A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy

NCT07378969 · clinicaltrials.gov ↗

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Malignancies of T-cell Origin

Sponsor

Novartis Pharmaceuticals